Circulating tumor cells as a marker of response: Implications for determining treatment efficacy and evaluating new agents

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 190-196

  Economos, Christina ^a   Morrissey, Colm ^a   Vessella, Robert L ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

circulating tumor cells; micrometastasis; prostate cancer; therapeutic response

Indexed keywords

BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BONE MARROW; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CHEMOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; DISEASE COURSE; METASTASIS; METASTASIS FREE SURVIVAL; MICROENVIRONMENT; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ANIMALS; HUMANS; MALE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859650845     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283519b58     Document Type: Review

References (49)

1. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791. (Pubitemid 39095313)
2. Cohen SJ, Punt CJ, Lannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20:1223-1229.
3. Hofman V, Ilie MI, Long E, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011; 17:827-835.
4. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for nonsmall cell lung carcinoma: Comparison of the efficacy of the cell search assay and the isolation by size of epithelial tumor cell method. Int J Cancer 2011; 129:1651-1660.
5. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003; 30:377-401. (Pubitemid 36520609)
6. Gronau E, Goppelt M, Harzmann R, Weckermann D. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. Onkologic 2005; 28:361-366. (Pubitemid 40827493)
7. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Actas Urol Esp 2009; 33:113-126.
8. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433-439. (Pubitemid 41124175)
9. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597. (Pubitemid 29211767)
10. Asworth TR. A Case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J 1869; 14:114-146.
11. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52:6110-6112.
12. Vessella RL, Blouke KA, Stray JE, et al. The use of the polymerase chain reaction to detect metastatic prostate cancer cells in lymph nodes and bone marrow [abstract]. Proc Amer Assoc Cancer Res 1992; 33:396.
13. Melchior SW, Corey E, Ellis WJ, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3:249-256. (Pubitemid 27107302)
14. Ellis WJ, Vessella RL, Corey E, et al. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and follow-up of patients with prostate cancer. J Urol 1998; 159:1134-1138. (Pubitemid 28172779)
15. Paez D, Labonte MJ, Bohanes P, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2011. [Epub ahead of print] Assesses the mechanisms responsible for the early dissemination of DTC and the theoretical pathways of DTC transition from dormant to proliferative states.
16. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10:871-877. Examines dormancy characteristics of DTC/CTC and their potential use as a preventive treatment for the abatement of cancer recurrence in long-term breast cancer survivors.
17. Cama C, Olsson C, Raffo AJ, et al. Molecular staging of prostate cancer: II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995; 153:1373-1378.
18. Sourla A, Lembessis P, Mitsiades C, Dimopoulos T. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res 2001; 5:3565-3567.
19. Zhang Y, Zippe CD, Lente FV, et al. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 1997; 3:1215-1220. (Pubitemid 27319769)
20. Grasso YZ, Gupta MK, Levin HS, et al. Combined Nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998; 58:1456-1459. (Pubitemid 28193608)
21. Park Y, Kitahara T, Urita T, et al. Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol 2011; 2:303-310.
22. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet 2009; 10:233-239.
23. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-6309.
24. Goodman OBJ, Symanowski JT, Loudyi A, et al. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 2011; 9:31-38. One of the few articles that examines the role of CTC in treatment efficacy of hormone sensitive rather than castrate resistant patients.
25. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis markers in progressive, castration-resistant prostate cancer. Clin Cancer Res 2007; 23:7053-7058. (Pubitemid 350276887)
26. Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010. doi:10.1155/2010/ 426218. [Epub ahead of print] This article deals with the importance the technical and statistical considerations in the detection/enumeration of CTC.
27. Kollermann J, Weikert S, Schostak M, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormonal therapy. J Clin Oncol 2008; 26:4928-4933.
28. Weckermann D, Polzer B, Ragg T, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009; 27:1549-1556.
29. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008; 26:1148-1159.
30. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumor cells. Nat Rev Cancer 2008; 8:329-340. (Pubitemid 351596394)
31. Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60:897-904. An investigation into the role of CTC as a biomarker of sensitivity to Abiraterone treatment in CRPC patients.
32. Panteleakou Z, Lembessis P, Sourla A, et al. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 2009; 15:101-114.
33. Dharmasiri U, Balamurugan S, Adams AA, et al. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis 2009; 30:3289-3300.
34. Gleghorn JP, Pratt ED, Denning D, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10:27-29.
35. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450:1235-1239.
36. Stott SL, Hsu CH, Tsurkrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010; 107:18392-18397.
37. Dharmasiri U, Njoroge SK, Witek MA, et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem 2011; 83:2301-2309.
38. Moon HS, Kwon K, Kim SI, et al. Continuous separation of breast cancer cells from blood samples using multiorifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip 2011; 11:1118-1125.
39. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220:768-774. (Pubitemid 24376375)
40. Wan Y, Mahmood MA, Li N, et al. Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology. Cancer 2011. doi: 10.1002/cncr.26349. [Epub ahead of print]
41. Wang S, Owens GE, Tseng HR. Nano 'fly paper' technology for the capture of circulating tumor cells. Methods Mol Biol 2011; 726:141-150.
42. Chung YK, Reboud J, Lee KC, et al. An electrical biosensor for the detection of circulating tumor cells. Biosens Bioelectron 2011; 26:2520-2526.
43. Zheng S, Lin HK, Lu B, et al. 3Dmicrofilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 2011; 13:203-213.
44. Boutrus S, Greiner C, Hwu D, et al. Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labeled circulating cells. J Biomed Opt 2007; 12:020507.
45. Arya M. The metastatic cascade in prostate cancer. Surg Oncol 2006; 15:117-128. (Pubitemid 46241866)
46. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571.
47. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22:941-950. (Pubitemid 351689875)
48. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005; 105:2631-2639. (Pubitemid 40446251)
49. Holcomb IN, Grove DI, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008; 68:5599-5608.